Mini-review explores oxidized mannan-conjugated MOG peptide for multiple sclerosis immunotherapy
New MS Treatment Could Teach Immune System To Stop Attack
This mini-review summarizes preclinical evidence on oxidized mannan-conjugated MOG peptide (OM-MOG35-55) for multiple sclerosis.
A new treatment for multiple sclerosis may teach the immune system to stop attacking nerves without shutting down protection or causing majo…
Plasma cytokines and CSF ROS measured in MS phenotypes show associations with disability and cognition
New Clues Explain Why Some MS Patients Lose Mobility Without Inflammation
This multicenter cohort study measured plasma cytokines and CSF ROS in participants with MS and other neurological disorders.
A new study reveals that in a form of progressive MS without active inflammation, brain stress signals—not inflammation—predict disability a…
Composite Endpoints Show Weaker Treatment Effects Than EDSS Alone in Multiple Sclerosis Trials
Adding walk tests to MS disability scores actually hides treatment benefits
This post-hoc analysis of ten phase III trials involving 9369 patients with relapsing-remitting and progressive multiple sclerosis evaluated…
Adding walk tests to standard disability scores actually hides treatment benefits in multiple sclerosis trials.
Narrative review notes lack of comprehensive synthesis on antioxidant strategies for multiple sclerosis
New MS Strategy Targets Hidden Nerve Damage Cycle
This narrative review examines antioxidant-based therapeutic strategies for multiple sclerosis.
Scientists are finding new ways to stop the cycle that destroys nerves in MS.
Simulation study of frontier AI models analyzing 10,000 synthetic Multiple Sclerosis cases reveals variable diagnostic safety
AI Doctors Miss Critical Clues in 10,000 Tests
This simulation study reviewed 10,000 synthetic Multiple Sclerosis cases analyzed by frontier artificial intelligence models against ground-…
Imagine walking into a clinic with a severe headache.
Observational study finds lower delayed recall ratios in multiple sclerosis patients versus controls
Memory fades faster in multiple sclerosis, study finds
This observational study abstract compares memory recall in 127 participants, including 62 multiple sclerosis patients and 65 controls.
People with MS forget more after a week than healthy peers. A simple memory test may spot cognitive decline earlier.
Systematic review and meta-analysis of CBT for depression in multiple sclerosis patients
New NEJM Analysis: CBT Works for MS Depression—No Matter How You Get It
This systematic review and meta-analysis evaluated cognitive behavioral therapy (CBT) for depressive symptoms in patients with multiple scle…
This analysis proves that depression treatment for MS patients can fit their lifestyle, not the other way around.
Narrative review examines resveratrol in Alzheimer's, Parkinson's, MS, and cerebral ischemia with noted limitations
This Common Food Compound May Shield Your Brain From Damage
This narrative review evaluates resveratrol across Alzheimer's disease, Parkinson's disease, multiple sclerosis, and cerebral ischemia.
A natural compound found in berries shows promise for protecting brain cells, but human proof is still missing.
Observational study abstract reports AI RNA sequencing diagnostic accuracy in multiple sclerosis and neuromyelitis optica
Artificial Intelligence identifies early Multiple Sclerosis and separates it from others
This abstract describes an observational diagnostic accuracy study involving 997 participants.
Artificial Intelligence analyzes blood cells to tell early Multiple Sclerosis apart from healthy people and similar conditions like Neuromye…
Higher serum MOG protein levels associated with MS diagnosis and disease activity compared to controls
MS Blood Test Could Reveal Flares Before They Strike
This case-control study examined serum myelin oligodendrocyte glycoprotein (MOG) protein levels in multiple sclerosis (MS) patients versus h…
This study suggests a simple blood test could one day help doctors spot MS flare-ups before they cause damage, offering a new tool to manage…
Switching therapy after rituximab resistance in AQP4-IgG+ NMOSD shows variable relapse outcomes
New Hope for Tough-to-Treat Nerve Disorder
This single-center, retrospective case series of 10 adults with AQP4-IgG+ NMOSD who were resistant to rituximab evaluated switching therapy.
Patients with a rare nerve disease who stopped responding to standard treatment found relief after switching to new therapies that prevented…
Elevated CSF and blood sCD27 associated with autoimmune disease in severe psychiatric disorders and MS
Could a simple protein in spinal fluid reveal hidden autoimmune disease in psychiatric patients?
This cohort study measured soluble CD27 (sCD27) in cerebrospinal fluid and blood from patients with severe psychiatric disorders, multiple s…
A simple spinal fluid protein may reveal hidden autoimmune disease in psychiatric patients who show signs of neuroinflammation.